Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study

The International Journal of Neuropsychopharmacology
Jan-Henry StenbergGrigori Joffe

Abstract

Mirtazapine added to antipsychotics appears to improve the clinical picture of schizophrenia, including both negative and positive symptoms. This study explored the effect of adjunctive mirtazapine on neurocognition in patients with schizophrenia who had shown an insufficient response to first-generation antipsychotics (FGAs). Thirty-seven schizophrenia patients, who were at least moderately ill despite their FGA treatment, received add-on mirtazapine (n=19) or placebo (n=18) in a 6-wk double-blind, randomized trial. Widely used neuropsychological tests were performed to explore visual-spatial functions, verbal and visual memory, executive functions, verbal fluency and general mental and psychomotor speed. The data were analysed on the modified intent-to-treat basis with last observation carried forward. False discovery rate was applied to correct for multiple testing. Mirtazapine outperformed placebo in the domains of visual-spatial ability and general mental speed/attentional control as assessed by, correspondingly, Block Design and Stroop dots. The difference in the degree of change (i.e. change while on mirtazapine minus that on placebo) was 18.6% (p=0.044) and 11.1% (p=0.044), respectively. Adjunctive mirtazapine might off...Continue Reading

References

Jan 1, 1966·Acta Psychologica·A R Jensen, W D Rohwer
Nov 15, 1994·Biological Psychiatry·E V SullivanA Pfefferbaum
Dec 1, 1994·Schizophrenia Research·P NopoulosN Andreasen
Feb 1, 1994·Archives of General Psychiatry·A J SaykinR C Gur
Jan 1, 1994·The American Journal of Psychiatry·J J Blanchard, J M Neale
Nov 14, 1997·International Clinical Psychopharmacology·D R Weinberger, B Gallhofer
Jul 23, 1998·Neuropsychology·R W Heinrichs, K K Zakzanis
Oct 19, 2001·CNS Drug Reviews·S A Anttila, E V Leinonen
Jan 18, 2003·Science·Steven E Hyman, Wayne S Fenton
Mar 26, 2003·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Michael PoyurovskyRonit Weizman
Mar 24, 2004·Schizophrenia Research·Gitry HeydebrandJohn G Csernansky
Apr 30, 2004·CNS Spectrums·Joseph I FriedmanJack M Gorman
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Nov 18, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Pamela RizkThomas Debeir
Oct 13, 2006·European Archives of Psychiatry and Clinical Neuroscience·Margot AlbusHelmut Küchenhoff
Jun 6, 2007·Archives of General Psychiatry·Richard S E KeefeUNKNOWN Neurocognitive Working Group
Jun 15, 2007·Schizophrenia Bulletin·Richard S E Keefe, Wayne S Fenton
Jan 4, 2008·The American Journal of Psychiatry·Keith H NuechterleinStephen R Marder
Jan 9, 2008·Experimental and Clinical Psychopharmacology·Roberto Delle ChiaieMassimo Biondi
Jan 22, 2008·Journal of Clinical Psychopharmacology·Joseph I FriedmanPhilip D Harvey
Feb 5, 2008·The American Journal of Psychiatry·Philip D Harvey, Barbara A Cornblatt
Apr 2, 2008·The British Journal of Psychiatry : the Journal of Mental Science·Andrei SzökeMarion Leboyer
May 27, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·E N RizosL Lykouras
Sep 4, 2008·Psychopharmacology·Cherrie Galletly
Sep 16, 2008·Schizophrenia Research·Shahin AkhondzadehSaeedeh Forghani

❮ Previous
Next ❯

Citations

Feb 4, 2014·Psychopharmacology·Jan BrosdaHeinz H Pertz
Mar 16, 2011·Progress in Neuro-psychopharmacology & Biological Psychiatry·Jan-Henry StenbergGrigori Joffe
Sep 29, 2011·Pharmacotherapy·Stephanie V Phan, Tiffany-Jade M Kreys
Jun 8, 2011·Expert Opinion on Pharmacotherapy·Sophiya Benjamin, P Murali Doraiswamy
May 21, 2015·The International Journal of Neuropsychopharmacology·Viacheslav TerevnikovJan-Henry Stenberg
Dec 16, 2011·Schizophrenia Research·Eric Michael Hecht, David C Landy
Sep 23, 2014·Schizophrenia Research·Jeffrey A VernonChristoph U Correll
Mar 16, 2013·Clinical Schizophrenia & Related Psychoses·Carol VidalSeth Himelhoch
May 22, 2010·Journal of Occupational Rehabilitation·Christopher R ReidSamiullah K Durrani
Dec 21, 2011·Culture, Medicine and Psychiatry·Elizabeth Bromley
May 29, 2018·The Cochrane Database of Systematic Reviews·Luke A PerrySuzanne Stricklin

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here